Many people still evaluate menopause hormone therapy through outdated headlines. Current guidance is more nuanced: treatment decisions depend on symptom burden, age, time since menopause, and personal risk history. A personalized plan is more informative than one-size-fits-all messaging.

Myth: everyone has the same risk profile

Risk differs by formulation, route, dose, and patient history. Transdermal options may be preferred in some cardiovascular risk contexts, while progestogen choices can alter tolerability. Absolute risk, not just relative risk, should be part of counseling.

Myth: hormones are only for hot flashes

Vasomotor symptoms are common, but therapy discussions may also include sleep disruption, mood changes, genitourinary symptoms, and quality-of-life impact. Local therapies may be considered when symptoms are primarily urogenital.

Myth: once started, therapy cannot be adjusted

Menopause care is dynamic. Clinicians can titrate dose, change routes, reassess duration, or transition to non-hormonal strategies as priorities change. Regular follow-up turns treatment into a tailored long-term strategy rather than a fixed protocol.

Myth: hormone therapy always causes breast cancer

The truth is more nuanced. Combined estrogen-and-progestogen therapy is associated with a small increase in breast cancer risk with longer-term use, roughly comparable in size to the effect of drinking alcohol regularly or being overweight. Estrogen alone, used by women who have had a hysterectomy, has not shown the same increase, and some long-term data suggest a possible reduction. Regular screening mammograms remain important whichever treatment you choose.

Myth: you should take the lowest dose for the shortest time, no matter what

Older guidance advised limiting treatment to a set number of years. Current recommendations are more flexible: the right dose and duration depend on your symptoms, your age, and your risk profile, and they should be reviewed at least once a year. Some women do well stopping after a few years, while others choose to continue because symptoms return or because they want the bone protection. Neither is wrong, and stopping gradually is often easier than stopping abruptly.

Myth: bioidentical means safer

Bioidentical hormones are chemically identical to those in the body, and several approved products are bioidentical. The label alone does not make a product safer, and custom-compounded versions have not been shown to be better than approved ones. Our bioidentical hormone guide explains how to tell the difference between approved and compounded products.

Myth: you have to wait until your periods stop

You can discuss treatment during perimenopause, when symptoms are often at their worst. Dosing may need more adjustment while your own hormones are still fluctuating, but waiting is not required. Starting earlier in the transition is associated with the most favourable balance of benefits and risks.

How to separate good advice from bad

Check whether the source cites current guidelines, such as those from the Menopause Society, and whether it discusses both benefits and risks. Be wary of absolute language like "always" or "never," of anyone selling something alongside the advice, and of claims that doctors are hiding the truth. A sound source will say what is known, what is uncertain, and when you should seek individual advice. Our article on the WHI study shows how headline findings can mislead.

Myth: hormone therapy is only for women with severe symptoms

Severity matters, but it is not the only reason women choose treatment. Some start because of sleep loss, vaginal discomfort, or concern about bone health, even when hot flashes are mild. Others find that once their symptoms are controlled, they feel more like themselves at work and at home. The right question is how much your symptoms affect your quality of life, not whether they meet some threshold of suffering.

Myth: non-hormonal options do not work

For women who cannot or prefer not to use hormones, there are several evidence-based alternatives. Fezolinetant, a newer non-hormonal medicine, targets the brain pathway behind hot flashes. Low-dose paroxetine, venlafaxine, and gabapentin reduce hot flashes by a meaningful amount for many women, though less than estrogen does. Cognitive behavioural therapy helps with how bothersome symptoms feel and with sleep. Discuss these openly, since the best plan is sometimes a combination.

Myth: you will get fat on HRT

Studies have not shown that hormone therapy causes weight gain. Weight tends to creep up in midlife because of age, lost muscle, poor sleep, and reduced activity. What estrogen loss does change is where fat is stored, moving it towards the waist. Therapy may help blunt that shift, but it is not a weight-loss treatment. Our menopausal weight gain guide explains what does help.

Myth: telehealth HRT is not real medical care

A properly run telehealth service involves a licensed clinician who reviews your history, orders any needed tests, prescribes within medical guidelines, and follows up. That is the same clinical process as an office visit, delivered remotely. The difference between good and poor telehealth is in the quality of screening and follow-up, which is why our provider checklist focuses on those questions.

What to remember

Hormone therapy is a medical treatment with real benefits and real, mostly small, risks, and the right choice varies from one woman to the next. Be sceptical of anyone who tells you it is either miraculous or dangerous in all cases. Bring your questions and your history to a qualified clinician and revisit the decision regularly.